C. Christophyllakis

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

John Souglakos, N. Ziras, Stylianos Kakolyris et al. · British Journal of Cancer · 2012 · 64 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study

Eleni‐Kyriaki Vetsika, Soultana Christou, Dora Hatzidaki et al. · Annals of Oncology · 2011 · 50 citations · Full text

Medicine, Immunology, Oncology +16

Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer

Dimitriοs Mavroudis, Pavlos Papakotoulas, Alexandros Ardavanis et al. · Annals of Oncology · 2009 · 44 citations

Medicine, Oncology, Pharmacology +11

Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial.

L. Vamvakas, Sofia Agelaki, Athanasios Karampeazis et al. · Journal of Clinical Oncology · 2010 · 37 citations

Medicine, Oncology, Pharmacology +11

A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer

K. Tryfonidis, Ioannis Boukovinas, Nikolaos Xenidis et al. · The Breast · 2013 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17